Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series B Warrants [Member] Common Stock [Member]	Series B Warrants [Member] Additional Paid-in Capital [Member]	Series B Warrants [Member]	Investment Banker [Member] Common Stock [Member]	Investment Banker [Member] Additional Paid-in Capital [Member]	Investment Banker [Member]	Investor Relations Consultant [Member] Common Stock [Member]	Investor Relations Consultant [Member] Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]	GLG Pharma, LLC. [Member] Common Stock [Member]	GLG Pharma, LLC. [Member]	Former CEO [Member] Common Stock [Member]	Former CEO [Member] Additional Paid-in Capital [Member]	Former CEO [Member]	The 2016 Registered Direct Offering [Member] Common Stock [Member]	The 2016 Registered Direct Offering [Member] Additional Paid-in Capital [Member]	The 2016 Registered Direct Offering [Member]	Over-Allotment Option [Member] Common Stock [Member]	Over-Allotment Option [Member] Additional Paid-in Capital [Member]	Over-Allotment Option [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2015																					$ 18,950	$ 2,080	$ 44,584,118	$ (40,492,437)		$ 4,112,711
Balance (in shares) at Dec. 31, 2015																						208,259
Shares issued for two options exercised at $65.75 per share (in shares)																						1,312
Shares issued for two options exercised at $65.75 per share																						$ 13	86,240			86,253
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering																					(18,158)	$ 664	17,494			0
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering (in shares)																						66,396
Shares issued for cashless Series A warrant exercises per the break-up of the Unit from the 2015 public offering (in shares)	628,237																					2,318,663
Shares issued for cashless Series A warrant exercises per the break-up of the Unit from the 2015 public offering	$ 6,282	$ 150,777	$ 157,059																			$ 23,187	556,479			579,666
Stock Issued During Period Shares Warrants Exercised	628,237																					2,318,663
Shares issued for cashless Series B warrant exercises per the tender offer exchange	$ 6,282	$ 150,777	$ 157,059																			$ 23,187	556,479			579,666
Stock Issued During Period, Shares, Issued for Services				135,995
Shares Issued				$ 1,360	$ 508,620	$ 509,980
Stock Issued During Period, Shares, New Issues							26,000			400,000		20,000			756,999
Stock Issued During Period, Value, New Issues							$ 260	$ 116,740	$ 117,000	$ 4,000	$ 4,000	$ 200	$ 90,151	$ 90,351	$ 7,570	$ 1,618,335	$ 1,625,905
Vesting Expense																							165,271			165,271
Unrealized gain from marketable securities																									$ 1,501	1,501
Corrections due to rounding for reverse split and DTCC increase (in shares)																						2,567
Corrections due to rounding for reverse split and DTCC increase																						$ 28	(29)			(1)
Net loss																								(6,526,014)		(6,526,014)
Balance at Dec. 31, 2016																					792	$ 45,644	47,894,196	(47,018,451)	1,501	923,682
Balance (in shares) at Dec. 31, 2016																						4,564,428
Stock Issued During Period, Shares, New Issues																		175,000				1,750,000
Stock Issued During Period, Value, New Issues																		$ 1,750	$ 392,000	$ 393,750		$ 17,500	3,403,688			3,421,188
Vesting Expense																							587,444			587,444
Unrealized gain from marketable securities																									$ (1,501)
Net loss																								(1,341,847)		(1,341,847)
Balance at Mar. 31, 2017																					$ 792	$ 64,894	$ 52,277,328	$ (48,360,298)		$ 3,982,716
Balance (in shares) at Mar. 31, 2017																						6,489,428